


**Product Name** : NX-2127  
**Cat. No.** : PC-20560  
**CAS No.** : 2416131-46-7  
**Molecular Formula** : C<sub>39</sub>H<sub>45</sub>N<sub>9</sub>O<sub>5</sub>  
**Molecular Weight** : 719.85  
**Target** : PROTAC  
**Solubility** : 10 mM in DMSO



CAS: 2416131-46-7

## Biological Activity

NX-2127 (Zeledromide) is a hetero-bifunctional, orally active **PROTAC** that induces the degradation of **BTK** and IKZF3 ubiquitination and proteasomal degradation in cells through recruitment of cereblon (CRBN).

NX-2127 degrades BTK in multiple B cell lymphoma lines with DC50 values in the range of 1-13 nM.

NX-2127 displays efficient cellular degradation yet binds to WT and mutant BTK with affinities that render covalent and noncovalent BTK inhibitors ineffective.

NX-2127 drives cellular ternary complex formation between BTK and CRBN by inducing positive cooperativity in both WT and acquired resistance mutant settings.

NX-2127 induces potent degradation of C481S, T474I, V416L, and L528W-mutant BTK and suppresses activation marker expression on cells harboring these mutations.

NX-2127 demonstrates oral bioavailability across pre-clinical species and shows robust tumor growth inhibition in WT and mutant mouse models of lymphoma upon once daily PO dosing.

## References

Jeffrey T. Mihalic, et al. **Cancer Res** (2023) 83 (7\_Supplement): 3423.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com